VivoSeq
Metabolic & Endocrine

Lipodystrophy

18

Pipeline Programs↗

2

Active Trials↗

12

Companies Involved↗

Lipodystrophy is an emerging landscape with 18 programs across 12 companies. The most active players are Intercept Pharmaceuticals, Roche, Chiesi Farmaceutici S.p.A.. 8 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

30/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Intercept Pharmaceuticals

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

ApprovedA

Agouron Pharmaceuticals

2 programs

ApprovedBristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

21 of 22 classified programs — the dominant modality here.

5%ALL OTHERSPeptide15%

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed17 · 81%
Unknown status2 · 10%
Recruiting1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Recruiting·AAmryt Pharma·Phase 3·NCT06502990·15 enrolled
Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy
Active, not recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT02262832·24 enrolled
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Completed·—·Phase 2·NCT02430077·10 enrolled
Leptin to Treat Lipodystrophy
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00005905·20 enrolled
Therapeutic Approaches to HAART-Induced Lipodystrophy
Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00461552·23 enrolled
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT00006185
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
Completed·—·N/A·NCT01511016·17 enrolled
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 4·NCT00135356·219 enrolled
Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Completed·HHospital Clinic of Barcelona·Phase 4·NCT00646984·147 enrolled
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT01023620·4 enrolled
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Completed·TTheratechnologies·Phase 3·NCT00608023·263 enrolled
Leptin to Treat Lipodystrophy
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00025883·103 enrolled
TH9507 in Patients With HIV-Associated Lipodystrophy
Completed·TTheratechnologies·Phase 3·NCT00123253·412 enrolled
Identification of a New Gene Involved in Hereditary Lipodystrophy
Completed·UUniversity Hospital, Bordeaux·N/A·NCT02056912·2 enrolled
Mechanisms of Lipodystrophy in HIV-Infected Pateints
Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00457665·56 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)